aibioBio-Path sells small Regulation A lots and hires a strategic advisor
Tickers BPTH
Bio-Path reports two small share sales under its Regulation A offering and an advisory engagement to find a buyer, partner or licensor.
Key facts
- Company
- Bio-Path Holdings, Inc. (OTC: BPTH)
- News type
- Financings
- Primary source
- Bio-Path Holdings, Inc. 8-K (2026-07-16)
Bio-Path Holdings, Inc. (OTC: BPTH) disclosed in a Form 8-K dated July 16, 2026 that it sold common shares in two sales under its Tier 1 Regulation A offering and engaged Farrington Capital Group LLC to find a strategic investor, buyer, joint venture partner or licensor for its biotechnology and intellectual property. The filing also reports board approval of a new Series B Preferred stock class and a series of other transactions the company describes as part of a strategic turnaround.
The share sales
On April 30, 2026, the company sold 466,100 common shares to a third party for $13,983 in net proceeds. On May 13, 2026, it sold 489,200 common shares for $14,676 in net proceeds. The company says it can raise an additional $571,341 under the qualified offering, though it says there can be no assurances. The filing names no underwriter or placement agent for either sale.
The Series B Preferred
On July 14, 2026, the board of directors and the Control Shareholder approved a new class of Series B Preferred stock with five million authorized shares. Each Series B Preferred share is convertible into 1,000 common shares, votes on an as-converted basis, pays no dividends and has no liquidation amount above its par value of $0.01.
The advisory engagement
On July 3, 2026, the company engaged Farrington Capital Group LLC, which the filing describes as a strategic advisory firm focused on education, biotech and real estate. The firm was engaged to identify and close a strategic investor, buyer, joint venture partner and/or licensor for the company's biotechnology and intellectual property, including its Phase 1 and Phase 2 drug trials targeting blood cancer, solid tumors, obesity and other domains. Bio-Path agreed to give the firm a 60-day exclusivity period to move discussions forward with at least one candidate it had identified. Any fees will be success-based, and no shares or cash were issued as a retainer. The engagement agreement is filed as Exhibit 10.1.
Clinical and cash items
On June 5, 2026, UT MD Anderson Cancer Center agreed to restart the company's Phase 2 trials targeting acute myeloid leukemia, subject to Bio-Path bringing them current on monies due. The filing lists $292,264.21 for trial BP1001-201-AML and $63,286.55 for trial BP1002-201-AML. The company believes the BP1001 trial can be restarted using cash from outside investors under its Tier 1 Regulation A offering and federal grants that it intends to pursue through consultants.
On June 26, 2026, the company opened a Coinbase Global account for an AI-driven digital asset treasury and says it may allocate up to 50% of capital raised to crypto opportunities.
Subsidiary and advisory transactions
On July 6, 2026, the company issued Series B Preferred shares for Series B and Series M Preferred shares of Himalaya Technologies, Inc., valued at $670,260, which the filing says makes Himalaya a majority owned subsidiary. On July 14, Himalaya mutually terminated a strategic development agreement with a third party.
On July 14, the company added Richard Fetyko, chief executive of altFINS, to its advisory board.
Financial position
The annual report on Form 10-K filed March 27, 2025, for 2024, reports research and development expense of $7.3 million for 2024 and $11.6 million for 2023. The net loss was $9.9 million for 2024 and $16.1 million for 2023. Cash from operations was negative $10.6 million in 2024 and negative $11.5 million in 2023. The company's quarterly report filed May 20, 2026 reports year-end 2024 cash and cash equivalents of $1.2 million and cash and cash equivalents of $12,000 at March 31, 2026.
The risks ahead
Bio-Path describes itself as in the midst of a strategic turnaround, and the filing says there are no assurances that any of its efforts will succeed. Cash was $12,000 at March 31, 2026, the Regulation A offering has raised only small sums so far, and MD Anderson will restart the Phase 2 trials only once the company pays the amounts it owes. The company says it may restart trials, sell or license its intellectual property, raise outside capital or pivot to blockchain tools for its drug work. The filing gives no price or terms for any buyer or partner.